Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered common stock offering by Atreca, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “BCEL.”
Atreca is a biopharmaceutical company utilizing a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.
The Davis Polk corporate team included partner Emily Roberts and associates Benson Richards and Sarah Kirk. The tax team included partner Po Sit and associate Tomislava Dragicevic. Partner Frank J. Azzopardi, counsel Daniel F. Forester and associate Daniel P. Kearney provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate J. Taylor Arabian provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.